GleamWall
中文EN

HYEX HEALTHY EXTRACTS INC.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1630176 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY66.9%
TTM net income YoY-87.1%
TTM EPS YoY—
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—

Margins

Gross margin62.4%
Operating margin—
Net margin-36.7%
FCF margin—
EBITDA margin—

Returns

ROE-9.7%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.21x

Leverage & solvency

Liabilities / assets34.0%
Debt / equity0.00x
Current ratio0.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.33x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.51M$3.11M
Cost of revenue$2.09M$1.20M
Gross profit$2.42M$1.91M
SG&A expense$3.37M$2.09M
Income tax$0$0
Net income-$881,119-$840,671
EPS (diluted)——
Banking
Net interest income-$210,279-$186,252
Balance sheet
Cash & equivalents$146,935$112,020
Receivables$187,750$11,003
Inventory$843,357$1.36M
Current assets$1.33M$1.66M
Goodwill$21.12M$193,260
Intangibles$4.23M$3,445
Total assets$27.82M$2.38M
Current liabilities$1.76M$1.34M
Total liabilities$3.80M$1.97M
Shareholders' equity$24.03M$410,377
Shares outstanding16.87M2.99M
Cash flow statement
Operating cash flow$165,520$281,968
Investing cash flow$56,301$0
Financing cash flow-$186,906-$189,389

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.